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Summary We have examined the anti-tumour activity of liposome-entrapped Adriamycin in a murine
metastatic tumour model produced by i.v. inoculation of J-6456 lymphoma cells and affecting predominantly
the liver. Sonicated liposomes containing phosphatidylcholine, a negatively-charged phospholipid and
cholesterol were used in these experiments. Liposome-entrapped Adriamycin was more effective than free
Adriamycin at equivalent doses of the drug. The superior thereapeutic effect of the liposome-associated drug
was manifest, either with a single i.v. treatment using a dose bordering the toxicity threshold of free
Adriamycin or with a multi-injection schedule using smaller doses. Based on the growth kinetics data of the J-
6456 lymphoma, our results indicate that tumour cell killing was enhanced by a factor of 100 using the
liposome associated form of Adriamycin. Histopathologic studies in mice bearing well-established metastases
of the J-6456 lymphoma in liver and spleen indicated that the extent and duration of pathologic remission
were significantly improved in mice receiving the liposome-entrapped drug as compared to mice receiving free
drug. No significant differences in the anti-tumour effect of liposome entrapped Adriamycin were observed
replacing phosphatidylserine by phosphatidylglycerol and reducing the cholesterol:phospholipid molar ratio
from 100% to 25%. In contrast to the metastatic tumour model, liposome-entrapped Adriamycin was
significantly less effective than free Adriamycin on the local i.m. growth of the J-6456 tumour. Altogether the
survival and histopathological data presented suggest that, with regard to a group of neoplastic conditions
with a predominant pattern of liver dissemination, a substantial increase in the therapeutic index of
Adriamycin can be achieved in a selective manner with the use of liposomes.
The use of liposomes as carriers of adriamycin
(ADM) seems to offer important advantages with
regard to the attenuation of the dose-dependent
anthracycline-induced cardiomyopathy. This effect
has been shown in rodents (Rahman et al., 1980,
1982; Forssen & Tokes, 1981; Olson et al., 1982)
and dogs (Herman et al., 1983) and is apparently
related at least partially to the reduced uptake of
the drug in the cardiac tissue of animals treated
with liposome-entrapped ADM (L-ADM) (Forssen
& Tokes, 1979, 1983; Rahman et al., 1980; Gabizon
et al., 1982, 1983; Olson et al., 1982). Obviously, if
this delivery system is to be useful therapeutically,
it is crucial to evaluate its anti-tumour activity.
Since liposomes home preferentially in tissues with
sinusoidal capillaries and rich in cells of the
reticuloendothelial system, such as the liver and
spleen (Segal et al., 1974; Poste et al., 1982), it is
reasonable to assume that tumour colonies residing
in these organs constitute a suitable target for
liposome-mediated delivery of cytotoxic drugs. The
purpose of this paper is to describe the antitumour
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activity of L-ADM examined in a tumour model (J-
6456 lymphoma) of hepatosplenic metastases.
In previous studies we showed that liposomes
containing negatively charged phospholipids
capture ADM very efficiently and cause important
changes in the tissue distribution of the drug, viz.
decreased levels in the heart and increased and
sustained levels in the liver and spleen. These
changes were observed in normal (Gabizon et al.,
1982) and in tumour-bearing mice (Gabizon et al.,
1983). Furthermore, when metastatic tumour cells
were isolated from the liver we found significantly
higher intracellular levels of ADM in tumour cells
of mice treated with L-ADM as compared to free
ADM treatment. Also, the proliferative ability of
intrahepatic metastatic cells in in vitro qultures and
in vivo transfer assays was markedly more impaired
after L-ADM treatment than after ADM alone
(Gabizon et al., 1983).
These results, and especially the ability of
liposomes to increase the intracellular levels of
ADM in liver-residing tumour cells, provided a
rational basis for therapeutic experiments. In the
present study, we have compared the survival of
tumour-inoculated mice treated either with L-ADM
or with free ADM using the metastatic liver model
of the J-6456 lymphoma. Our results suggest that
the therapeutic index of ADM can be significantly
improved by liposome association in a group of
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selected neoplastic processes and emphasize the
potential usefulness of this approach. Some of our
initial observations on therapeutic studies with the
J-6456 lymphoma have been previously reported
(Gabizon et al., 1982).
Materials and methods
Animals and tumour
Age- and sex-matched BALB/c mice from the
Animal Breeding Center of the Hebrew University
(Jerusalem, Israel) were used in these experiments.
Tumour cells were obtained from a BALB/c,
radiation-induced, T-cell derived lymphoma (J-6456)
described previously (Gabizon & Trainin, 1980).
Metastases to the liver and spleen occur after i.m.,
s.c., and i.v. inoculations of the J-6456 lymphoma.
This tumour is maintained by serial i.m. trans-
plantation in syngeneic mice and has undergone 7
i.m.-liver-i.m. cycles to select for liver-metastasizing
ability. The J-6456 tumour fits the description of
the BALB/c T-cell lymphocytic lymphoma according
to the classification proposed by Pattengale & Frith
(1983). Tumour cell suspensions were prepared
aseptically by trypsinization of minced pieces of the
tumour (0.25% trypsin, GIBCO, New York, N.Y.)
and washing with RPMI medium (GIBCO). The
viability of the cell preparations as determined by
the trypan blue exclusion test was >95%. Tumour
cells were injected either i.v. through the tail vein or
i.m. into the hind leg.
Mice were inspected daily and survival curves
recorded. Whenever possible, dead mice were
autopsied to assess the extent of tumour
involvement.
Preparation ofliposomes
Chromatographically tested, high purity (>99%)
phospholipid batches were obtained from Sigma
Chemical Co. (St Louis, MO) and from Lipid
Products (Surrey, UK). Cholesterol (Chol),
standard for chromatography, was obtained from
Sigma. ADM (vials containing 50mg doxorubicin-
HCI and 250mg lactose) was obtained from
Farmitalia-Carlo Erba (Milan, Italy). For the
preparation of liposomes, the lipids were mixed in a
round-bottom flask according to the composition
and the molar ratio specified in each experiment
and the lipid solvents were evaporated under
vacuum with a rotary evaporator. ADM
(5mgm1-1) in 0.9% NaCl solution was added to
the lipid film so as to reach a final concentration of
40Jmol phospholipid ml- . Liposomes were
formed by vortexing and subsequently submitted to
pulsed ultrasonic irradiation with a probe sonicator
(W-225, Heat Systems Ultrasonics, Plainview, NY)
for 15min, at 4°C under a continuous nitrogen
flow. Titanium particles were removed by centrifu-
gation of the liposome suspension at 2,000r/min
for 5min in a bench top centrifuge. The un-
entrapped drug was separated from the liposome-
entrapped drug by gel filtration on Sephadex G-50.
Sterilization of the liposome suspension was
accomplished by filtration through 0.4 and 0.2gm
Nucleopore membranes (Nucleopore Corporation,
Pleasanton, CA). The size range of the membrane-
filtered vesicles as determined by transmission
electron microscopy with phototungstic acid
negative staining was 40 to 180nm. The ADM
content of liposomes was determined from samples
diluted in acidified ethanol (0.3N HCI in 50%
ethanol) either fluorometrically with a Perkin-Elmer
MPF 44 spectrofluorometer (excitation: 490nm;
emission: 590nm) or by measuring the optical
density with a Gilford spectrophotometer, at
496nm wavelength. Fluorescence intensity and
optical density were translated to tg (fluorescence
and absorbance) or ng (fluorescence only) of ADM-
equivalents using standard curves of ADM. The
characteristics of the liposome preparations have
been previously discussed (Gabizon et al., 1982).
Briefly, 50-65% of the initial amount of ADM was
retained in the liposomes using a 3:7 molar ratio of
either phosphatidylserine (PS):phosphatidylcholine
(PC) or phosphatidylglycerol (PG):PC, respectively.
The final molar ratio of ADM to phospholipids in
the vesicles was - 12%. Liposomes were stored at
4°C in sterile, siliconized, vacuum-sealed tubes
(Vacutainer Systems, Rutherford, NJ) protected
from light. Liposomes were used within 3 weeks
after storage. Mice given injections of free ADM
received freshly prepared drug solutions.
Histological examinations
Light microscopy examinations were performed in
organs from tumour-inoculated mice with and
without treatment. Liver, spleen, and kidneys were
fixed in Bouin's solution and stained with
haematoxylin-eosin-phosphomolybdic acid: light
green stain. For details of the staining procedure
see Levi-Schaffer et al. (1982).
Statistical analysis
The statistical significance of the results was
evaluated by the non-parametric, ranking test of
Wilcoxon.
Results
Tumourigenic capacity ofi.v. inoculated J-6456 cells
Figure 1 shows linear regression analysis of theANTI-TUMOUR ACTIVITY OF LIPOSOME-ASSOCIATED ADRIAMYCIN 683
results obtained when the survival of mice
challenged i.v. with growing inocula of tumour cells
is plotted against the logarithm of the inoculum.
One hundred tumour cells were sufficient to grow
and eventually kill most of the animals (80-100%
depending on the experiment). No tumour takes
were observed after injection of 10 tumour cells.
According to this experiment the estimated period
of time required for one log increase of the J-6456
lymphoma is between 4 to 5 days.
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Figure 1 Linear regression of the size of tumour cell
inoculum plotted against the mean survival time of
inoculated mice. J-6456 cells were injected i.v. into
BALB/c X mice. No tumour takes were obtained in
mice inoculated with 101 tumour cells and observed for
60 days.
Figure 3 The effect ofchanges in theliposome composi-
tion on the antitumour activity of L-ADM. Schedule
of treatment indicated by arrows. (0 0)
Untreated mice; (0 O) Free ADM, 8mgkg 1;
(0--0*) L-ADM (PS:PC:Chol; molar ratio,
3:7: 10),8mgkg-';(O-- O)L-ADM(PS:PC:Chol;
molar ratio, 3:7:2.5), 8mgkg-1; (0---0
L-ADM (PG:PC:Chol, molar ratio, 3:7:10), 8mgkg-1;
(0 - r L-ADM (PG:PC:Chol; molar ratio,
3:7:2.5), 8mgkg-.
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Figure 2 Lack of enhancement of the anti-tumour
effect by the simultaneous administration of free ADM
and plain liposomes. Schedule of treatment indicated
by arrows. The lipid dose of mice receiving plain
liposomes and mice receiving L-ADM was the same:
6pmol phospholipids and 6jmol Chol per mouse.
(0 * *) Untreated mice; (0 O) Free
ADM, 8mgkg- 1; (Q---O) Plain liposomes
(PS:PC:Chol) and free ADM, 8 mgkg- 1; (0- )
L-ADM (PS:PC:Chol), 8 mgkg 1.
Comparison ofthe effects ofL-ADM andfree ADM
treatments on the survival oftumour-inoculated mice
The 106 cell inoculum was chosen for the
chemotherapeutic studies so that treatment efficacy
could be tested on a reasonably high tumour
Figure 4 Superior therapeutic activity of L-ADM as
compared to the maximal tolerated doses of free ADM
using a single i.v. injection 3 days after tumour inocu-
lation. (0 *) Untreated mice; (0---*)
Free ADM, 12mgkg-1 (toxic dose); (0- O)
Free ADM, l0mgkg- (subtoxic dose); (0--)
L-ADM (PG:PC:Chol), 12mgkg -'.
burden. Chemotherapy was administered not less
than 3 days after tumour injection to try not to
interfere with tumour cell arrest in target tissues
and initiation of proliferation. Table I shows the
results of the treatment with free ADM and L-
ADM at equal doses on the survival of mice
inoculated i.v. with the J-6456 lymphoma. In the
experiments presented in Table I, treatment
consisted of at least 3 weekly injections using a
non-toxic dose of ADM (8mgkg- 1). The
phospholipid dose per injection was 4-6ymol per
mouse. The administration of L-ADM resulted in a
reproducible and significant prolongation of
survival when compared to the effect of free ADM.
Free ADM was also active against the J-6456
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Table I Increased anti-tumour activity of L-ADMa
Survival time (days)
Exp. no. No. ofmice Mean+s.e. Median (range) pb
Untreated 5 21.0+0.6 20.0 (20-22) [<0.01
1 Free ADM 7 29.0+1.2 28.5 (24-32) [<0.01
L-ADM (PS:PC:Chol) 7 41.3+1.7 41.0 (34-48)
Untreated 7 19.3+0.5 18.5 (18-21) [<0.01
2 Free ADM 8 40.5+2.3 40.0 (28-50) <0.01 L-ADM (PG:PC:Chol) 8 71.1 + 12.9 53.0 (41-148)
Untreated 8 19.5+0.3 19.0 (18-21) < 01
3 Free ADM 9 32.1+1.1 30.0 (30-40) [<0-01
L-ADM (PG:PC:Chol) 9 44.8+1.3 43.5 (39-51)
Untreated 10 18.6+0.4 18.1 (17-21) [<0.01
4 Free ADM 10 27.3+0.6 26.5 (24-30) [<0.1
L-ADM (PS:PC:Chol) 8 48.5+6.8 45.0 (22-77)
Untreated 10 23.3+0.8 22.0 (24-28) 001
5 Free ADM 15 38.6+2.2 35.2 (31-60) [<0.01
L-ADM (PS:PC:Chol) 12 49.2+2.9 48.0 (36-70)
Untreated 7 21.7+1.8 19.8 (18-32) [<0.01
6 Free ADM 14 25.3+0.6 23.9 (23-33) [<001
L-ADM (PS:PC:Chol) 15 32.4+0.9 32.4 (26-41)
'BALB/c mice inoculated with 106 J-6456 cells and treated i.v. with 8mgkg-1 ADM in
either free or liposome-entrapped form according to the following schedule:
Days
Exp. 1: 3, 10, 17
Exp. 2: 3, 10, 17
Exp. 3: 3, 10, 17
Exp. 4: 3, 10, 17,24
Exp. 5: 3, 10, 17, 36, 46
Exp. 6:11, 18, 25,-32.
bWilcoxon test: Free ADM analyzed versus Untreated; L-ADM analyzed versus Free
ADM.
tumour but the increase in median life span
observed in experiments 1 to 5 was in the range of
42-116% as compared to 105-187% for L-ADM
treated mice. As expected the anti-tumour effect
observed was more marked if treatment was started
3 days after tumour inoculation (Experiments 1 to
5) instead of 11 days after tumour inoculation
(Experiment 6). Nevertheless, in the latter
experiment L-ADM was still significantly superior
to free ADM, indicating that the relative anti-
tumour efficacy of the liposome-associated drug is
not affected by the presence of a higher tumour
burden. Another point worth noting in Table I is
that increasing the number of treatments from 3 to
4 and 5 injections did not further improve the anti-
tumour effects observed. A rough evaluation of the
relative efficacies of these two modalities of
treatment can be inferred from our data on the
growth kinetics of the J-6456 lymphoma shown in
Figure 1. Since the log growth time of this tumour
is 5 days, and the differences in mean and median
survivals between free ADM-treated and L-ADM-
treated mice of experiments 1 to 5 were > 10 days,
the estimated cytoreductive effect of L-ADM in this
tumour model is 100 times higher than that of
free ADM. Exceptionally there were long-term
survivors with no macroscopic tumour recognizable
at autopsy among L-ADM treated mice only.
Association of ADM with liposomes was required
for the enhancement of the anti-tumour effect to
occur. As shown in Figure 2, free ADM injected
together with plain liposomes (mixed immediately
before injection) was not more effective than free
ADM alone. This indicates that simultaneous
administration of the drug with plain liposomes
does not lead to a synergistic anti-tumour effect.
We also investigated the effects of reducing the
Chol content of the liposomes and of substitutingANTI-TUMOUR ACTIVITY OF LIPOSOME-ASSOCIATED ADRIAMYCIN 685
PS by PG as the negatively-charged lipid com-
ponent. The results of this experiment are presen-
ted in Figure 3. Decreasing the Chol:phospholipid
molar ratio from 100% to 25% did not cause any
change in the in vivo anti-tumour activity of the
ADM-loaded liposomes. The survival curves shown
in Figure 3 also indicate that there was no
significant difference in the anti-tumour activity
using either PS or PG liposomes. This finding is in
agreement with the results obtained in Table I in
separate experiments.
In Figure 4, we compare the anti-tumour effect
of maximally tolerated doses of free ADM in single
bolus injection to an equivalent dose of L-ADM.
Using a dose of 12mgkg-1 of free ADM, a certain
degree of toxicity is seen (-LD 10). With the same
dose of L-ADM, no toxicity was observed and the
anti-tumour effect was superior to the toxic dose
(12mgkg-1) and to the maximally tolerated dose
(l0mgkg- 1) of free ADM.
The therapeutic effects of L-ADM and free ADM
were compared also on locally growing tumours
obtained by i.m. inoculation of the J-6456
lymphoma. Mice received 106 tumour cells i.m. into
the thigh and were treated i.v. with 8mgkg-' of
either free ADM or L-ADM on days 3, 10 and 17
after tumour inoculation. Median survivals were
22.0 (s.d. =3.3), 28.6 (s.d. = 1.5), and 36.0
(s.d.=7.9) days respectively for untreated, L-ADM
treated and free ADM treated mice. The differences
between untreated and L-ADM treated, on the one
hand, and between L-ADM treated and free ADM
treated, on the other hand, were both statistically
significant at the P<0.01 level (Wilcoxon test).
Thus clearly, free ADM was more effective than an
equal dose of L-ADM against tumour cells growing
locally in the i.m. site, while the superior
antitumour effect of L-ADM was expressed on
tumours located in selected anatomic areas such as
liver and spleen.
Histopathological study
An anti-tumour experiment was conducted for the
purpose of histopathological observations on
tumour growth and response to treatment. Mice
were inoculated i.v. with 106 J-6456 tumour cells
and 10 days later treated with either free or
liposome-entrapped ADM given in a single i.v. shot
at dose of 10 mgkg- '. Groups of mice were
sacrificed at days 10, 13, 17, 22 and 26 after
tumour inoculation, for examination.
Untreated mice showed after treatment a
progressive increase of liver and spleen weights
from day 10 after tumour cell injection and of
kidney weight from day 15 after tumour cell
injection. The weights of the livers of dying mice
were between 3.5 and 3.9 g as compared to the
normal liver weight which did not exceed 1.4g. The
spleen and kidney weights reached respectively
400mg (normal, 110mg) and 650mg (normal,
400mg). Grossly, there was hepatosplenomegaly
with focal areas of tumour involvement noticeable
in the liver and sometimes also in the kidneys.
All treated mice showed extensive regression of
tumour foci in the liver and spleen. Although the
pattern and timing of tumour regression was similar
with both treatment modalities, there was a
noticeable difference in the extent and duration of
the responses observed. As seen in Table II,
complete pathologic tumour regression was found
in only 2/12 mice treated with free ADM, whereas
among L-ADM-treated mice examined in the same
period of time, complete pathological remission
was present in 9/12 animals. The data ofTable II also
suggest that the liposome associated drug was
effective in preventing or delaying tumour
development in the kidneys. Figures 5, 6 and 7
show representative microscopic cross-sections of
the livers of untreated, free-ADM-treated and L-
ADM-treated mice, 3 days after drug injection.
Table II Anti-tumour effects of L-ADM and free ADM on the J-6456 lymphoma:
histopathological examinations.a
No. ofmice with microscopic tumour/no. ofmice examined
Days after Untreated Free ADM L-ADM
tumour
inoculation Liver Spleen Kidney Liver Spleen Kidney Liver Spleen Kidney
10 3/3 3/3 0/3
13 3/3 3/3 3/3 2/3 2/3 1/3 0/3 0/3 0/3
17 3/3 3/3 3/3 2/3 0/3 0/3 0/3 0/3 0/3
22 All dead 3/3 2/3 2/3 1/3 0/3 0/3
26 3/3b 3/3 3/3 2/3 1/3 2/3
aTreatment was administered 10 days after inoculation of the tumour and consisted of one i.v.
injection of ADM, 10mgkg-' in either free of liposome-encapsulated form.
bTwo out of 3 mice found dead.686 A. GABIZON et al.
This study did not reveal any significant toxic
effects on the normal liver and kidney tissues with
either form of treatment. In the spleen, severe
inhibition of erythro and myelopoiesis was observed
with both types of treatment. Between days 7 and
12 after drug administration haemopoietic function
of the spleen was restored to normal.
Discussion
The present study indicates that a significantly
increased life prolongation can be obtained using a
liposome-associated form of ADM to treat a
metastatic tumour with predominant spread to the
liver and spleen. Increased antitumour activity of L-
Figure 5 Representative field of a BALB/c mouse liver, 13 days after inoculation of 106 J-6456 tumour cells.
Multiple tumour cell foci with radial growth from the perivascular centrilobular area into the surrounding
parenchyma are seen ( x 200).
Figure 6 Representative field of a BALB/c mouse liver 13 days after inoculation of 106 J-6456 lymphoma
cells and 3 days after treatment with free ADM (10mgkg-i). A partially necrotic tumour cell focus is shown
( x 200).ANTI-TUMOUR ACTIVITY OF LIPOSOME-ASSOCIATED ADRIAMYCIN
Figure 7 Representative field of a BALB/c mouse liver 13 days after inoculation of 106 J-6456 lymphoma
cells and 3 days after treatment with L-ADM (10mgkg-'). No tumour cells are found ( x 200).
ADM on intrahepatic metastases albeit with a
phagocytic tumour, has been also shown by
Mayhew et al. (1983). These results are in agree-
ment with our previous data indicating increased
intracellular drug levels in liver-residing tumour
cells of mice treated with L-ADM as compared to
free ADM (Gabizon et al., 1983). The therapeutic
advantage of L-ADM over free ADM rests
apparently on a drug concentration effect in the
involved tissues, although it remains questionable
whether the drug is taken up by tumour cells
directly in its liposome-associated form or indirectly
after release from liposomes stored by the RES. In
this context, the possibility of ADM transfer from
macrophages into tumour cells has been reported
(Martin et al., 1982).
The activity of L-ADM appears to be dependent
on tumour location in specific anatomic areas
accessible to liposomes, such as liver and spleen.
This point is emphasized by the reduced effective-
ness of L-ADM found in mice with i.m. implanted
tumours. The question as to whether anatomical
barriers will determine differential access and
differential anti-tumour activities of liposome
delivered drugs in different body locations has
raised objections about the applicability of these
carriers in cancer chemotherapy (Poste, 1983).
However, the therapeutic activity of L-ADM on
tumour cells infiltrating the liver, spleen and,
probably the kidneys, as shown here, is a distinct
advantage which may outweight in selected
neoplastic conditions a possible reduced activity in
other locations.
It has been proposed that liposomes act by
providing a slow-release drug depot, improving the
pharmacokinetic properties of some drugs (Kaye et
al., 1981; Richardson & Ryman, 1982; Mayhew &
Papahadjopoulos, 1983). With phase-specific drugs,
such as cytosine arabinoside (Ara-C) and
methotrexate, the higher and sustained blood levels
appear to account for a superior antitumour
activity when compared to free drug bolus
injections (Richardson & Ryman, 1982). Indeed, it
has been reported that there is no difference in the
therapeutic efficacy comparing a single dose of
liposomal Ara-C with a 5-day infusion of free Ara-
C in an i.v.-tumour-i.v. treament model (Mayhew
et al., 1982). With regard to ADM, the factors
regulating the therapeutic index of the liposome
associated form seem to be different since it has
been recently reported that the therapeutic index of
24h infused free ADM is still inferior to that of L-
ADM (Mayhew & Rustum, 1984). We have found
previously (Gabizon et al., 1982) that the blood
levels of ADM are 10-100 times lower than those
already detected in the liver and spleen 1 h after
injection of ADM entrapped in negatively-charged
liposomes. Therefore, it is unlikely that the
circulating liposomal drug pool can account for a
prolonged exposure of accessible tumour cells to
ADM. However, a slow-release effect within the
tumour-involved liver may well be important in
determining the antitumour effect. In this context.
we have shown that the hepatic clearance of ADM
is prolonged in mice injected with the liposomal
drug (Gabizon et al., 1982). A similar finding was
reported by Kaye et al. (1981) for Actinomycin-D.
ADM has been incorporated to liposomes of
various compositions and prepared by different
methods. Obviously standardization of the liposome
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composition and procedure of preparation is
required if any pharmaceutical development is
considered. The addition of negatively-charged
phospholipids to PC ensures a high degree of drug
capture by the liposome bilayer (Goormaghtigh et
al., 1980; Gabizon et al., 1982). Based on these
consideration, we chose to carry out the in vivo
anti-tumour experiments with liposomes containing
either PG or PS as negatively charged phospho-
lipid. As shown in the present study, neither the
replacement of PS with PG, nor the reduction of
Chol content, significantly affected the anti-tumour
effect observed. However, if therapeutic appli-
cations of L-ADM are contemplated, PG should be
preferred to PS because it is less sensitive to lipid
oxidation processes affecting the head group
(Roseman et al., 1975) and can be readily obtained
from animal sources by a simpler enzymatic con-
version of PC (Comfurius & Zwaal, 1977). The fact
that the Chol:phospholipid molar ratio can be
decreased to 25% without any significant loss of
anti-tumour activity is consistent with the ability of
liposomes to withstand the deleterious effect of
serum proteins when the Chol content is kept above
20% (Pownall et al., 1979; Snyder & Freire, 1980).
This reduction of Chol content is important as it
allows to reduce the lipid load necessary to deliver
therapeutic doses of ADM.
In our studies, we have used sonication as a
means of obtaining a small sized vesicle population
with a reproducible size distribution. Small
liposomes (<100nm) can apparently reach the
parenchymal area of the liver to a significant scale
(Poste et al., 1982) and are more efficiently
incorporated by non-phagocytic cells when
compared to large-sized vesicles (Straubinger et al.,
1983; Machy & Leserman, 1983; Matthay et al.,
1984), suggesting that they constitute the most
advantageous vesicles for in vivo tissue penetrability
and delivery of cytotoxic drugs to tumour cells. It is
at present unclear whether drug-loaded vesicles of
similar size prepared by different methods such as
sonication, membrane extrusion, and French press
(reviewed by Szoka & Papahadjopoulos, 1980) have
the same biological activity.
Obviously, the potential clinical benefit of L-
ADM must be evaluated in the light of the reduced
acute and chronic toxicities reported with this
modality of administration (Rahman et al., 1980,
1982; Forssen & Tokes, 1981; Olson et al., 1982;
Herman et al., 1983). Since the superior antitumour
activity of L-ADM in the metastatic model is
already apparent at equal doses of free drug, and
the LD50 of ADM is significantly increased by
liposome association (Olson et al., 1982; Gabizon et
al., 1984), it can be inferred that liposome entrap-
ment improves the therapeutic index of ADM in a
selected group of neoplastic conditions. Yet it is not
possible to predict at this time, the actual scope of
clinical applicability in view of the broad hetero-
geneity of tumours with regard to factors such as
microvascular architecture (Shubik, 1982), nodular
versus diffuse growth, zonal differences in various
phenotypic characteristics (Fidler & Hart, 1981),
endocytic uptake of particular material and macro-
phage infiltration (Talmadge et al., 1981), all of
which may have important implications on
accessibility and uptake of liposomes.
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